Intellia Therapeutics saw a welcome improvement to its Relative Strength (RS) Rating on Monday, rising from 66 to 71.
Can You Really Time The Stock Market?
IBD's unique RS Rating tracks technical performance by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
Over 100 years of market history reveals that the stocks that go on to make the biggest gains often have an 80 or better RS Rating as they begin their largest price moves. See if Intellia Therapeutics can continue to rebound and hit that benchmark.
Intellia Therapeutics is not currently near a potential buy zone. See if the stock goes on to form a promising consolidation that could kick off a new climb.
Intellia Therapeutics reported 0% earnings growth in its most recent report, while sales growth came in at -43%. The next quarterly numbers are expected on or around Jul. 31.
Intellia Therapeutics earns the No. 260 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, Inhibrx Biosciences and TG Therapeutics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
